VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, including major depressive disorder, neuropathic pain social anxiety disorder and suicidal ideation. AV-101 is an oral NMDAR GlyB (N-methyl-D-aspartate receptor glycine B) antagonist, belonging to a new generation of investigational medicines in neuropsychiatry known as glutamate receptor modulators having the potential to treat Major Depressive Disorder faster than currently available FDA-approved antidepressants which, if effective, take many weeks to months to achieve therapeutic benefits. With the at-home convenience of an oral therapy, AV-101 has the potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants.
PH94B was developed from proprietary compounds called pherines. With nasal spray administration, PH94B acts locally on peripheral nasal chemosensory receptors that trigger rapid activation of the hypothalamic-limbic areas of the brain associated with social anxiety disorder. This mechanism of pharmacological action, the rapid onset of efficacy, and the excellent safety and tolerability profile shown in clinical trials make PH94B an excellent product candidate for the acute treatment of patients with social anxiety disorder, which affects as many as 15 million adults in the U.S.
343 Allerton Avenue
South San Francisco, CA 94080
Pharmaceutical Preparation Manufacturing (325412)
Pharmaceutical Preparations (2834)